G6PD Antibodies

Glucose-6-phosphate 1-dehydrogenase (G6PD)

Catalyzes the rate-limiting measure of the oxidative pentose-phosphate pathway, which represents a path for the dissimilation of carbohydrates besides glycolysis. The main role of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis.

.

Gene Information

Human
Gene Name:	G6PD
Uniprot:	P11413
Entrez:	2539

Family

Belongs to:
glucose-6-phosphate dehydrogenase family

Alternative Names

G6PD; G6PD1EC 1.1.1.49; G6PDH; glucose-6-phosphate dehydrogenase

Molecular Weight

Mass (kDA):
59.257 kDA

Genomic Context

Human
Location:	Xq28
Sequence:	X; NC_000023.11 (154531390..154547569, complement)

Tissue Specificity

Isoform Long is found in lymphoblasts, granulocytes and sperm.

Subcellular Localizations

Cytoplasm, cytosol. Membrane; Peripheral membrane protein.

Diseases

• Glucosephosphate Dehydrogenase Deficiency
• Anemia
• Hemolysis (disorder)
• Anemia, Hemolytic
• Malaria
• Icterus
• Neonatal Jaundice
• Hyperbilirubinemia
• Thalassemia
• Neoplasms
• Malaria, Falciparum
• Anemia, Sickle Cell

• Malignant Neoplasms
• Infective Disorder
• Diabetes Mellitus
• Enzymopathy
• Anemia, Hemolytic, Congenital Nonspherocytic
• Hyperbilirubinemia, Neonatal

Interacting Proteins

• HSPB1
• SIRT2

Pathways

• Localization
• Pathogenesis
• Methylation
• Glycolysis
• Cell Growth
• Cell Proliferation
• Aging
• Cell Death
• Transport
• Phagocytosis
• Coagulation
• Dna Methylation
• Regeneration

• Cell Cycle
• Dosage Compensation
• Reverse Transcription
• Secretion
• Metaphase
• Translation
• Embryo Development

PTMs

• Oxidation
• Phosphorylation
• Methylation
• Reduction
• Cleavage
• Glycosylation
• Acetylation
• Demethylation

• Decarboxylation
• Carboxylation
• Hydroxylation
• Nitration
• Glutathionylation
• Dephosphorylation
• Deacetylation
• Palmitoylation

Research Areas

• Cancer
• Cellular Markers
• Golgi Apparatus Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/G6PD

Boster Bio - Best Uses Of The G6PD Marker

Before we begin the review of Boster Bio Anti-Glucose 6 Phosphate-Dehydrogenase/G6PD Marker briefly go over the purpose of this reagent, what it can do for us, and what we can do to make the most of it. We will look at the application of the reagent, its the scalability and specificity, and validation.

Boster Bio Anti-Glucose 6 Phosphate Dehydrogenase/G6PD Marker

The Boster Bio Anti-Glucose 6 Phosphate Dehydrogenasen (G6PD) Marker was developed to aid in the detection of G6PD. It is available for flow Cytometry, IHC, ICC, and WB. It interacts with Human. G6PD is involved in the breakdown of carbohydrates in the body, and is an essential enzyme in this process.

G6PD enzyme activity can be found in a variety of tumors. It has been detected in lung and colon cancers as we caas digestive tract, renal ce cacarcinomas and breast cancers. Furthermore, it helps red blood ce cs function normally. Its role in human disease is not yet understood.

G6PD is a genetic disorder. Neonatal hyperbilirubinemia is a possibility in those deficient in this enzyme. G6PD deficiency may also cause chronic hemolysis. A CLIA-certified laboratory is required in order to carry out the test. Dr Lal PathLabs, one of India's leading blood test labs, is available. You can get online results from this lab.

Boster Bio Antiglucose 6Phosphate dehydrogenase (G6PD), is a type 1 membrane with a single-pass protein that is found in ce cs' endosomes, as we caas the retina. G6PD is a protein which is extremely present in human ce cs and could be lacking in some instances.

G6PD has been linked to Melanoma. However, the role of G6PD in melanoma remains unclear. Research indicates that G6PD may play a crucial role in the development of melanoma as we caas its progression. Boster Bio Anti-Glucose Six-Phosphate-Dehydrogena marker

Applications

The G6PD gene is a monomer composed of 515 amino acids with a molecular mass of 59 kg. The protein requires NADP+ to activate the enzymatic activity and forms an tetramer or dimer after removal of the NADP+ from its inactive form. Despite its complexity physicochemically, G6PD is extensively used to identify genetic disorders and the cause of many human illnesses.

G6PD is an important regulator of the pentose-phosphate pathway. It produces nicotinamide dinucleotidephosphate (NADP) which is responsible for maintaining a healthy reducing environment in ce cs, especially red blood ce cs. Mutations in G6PD could cause an imbalance in the redox system of the body. If not addressed promptly it can cause neonatal jaundice or acute hemolytic anemia.

The lack of access to diagnostics in the tropical Africa can lead to a delayed diagnosis of sickle-ce cadisease. In such cases, the G6PD marker can help doctors map the distribution of inherited diseases and define their patterns. This information is essential for large-scale interventions. The field of Molecular Epidemiology is a significant field of research. For instance, determining the genetic susceptibility of a patient to different diseases can help to prevent the spread of deadly infections.

A 919-bp segment from the G6PD gene was digested by NlaIII and SmI in PCR. This enzyme allowed for the distinction of genotypes 126N and126D. Similarly, the 358-bp fragment of the HbB gene was digested using MnlI as we caas DdeI. The PCR products were observed with a 1,5% agarose Gel.

Specificity

The sensitiveness and specificity of this test depend on the expression level of G6PD in a tumor. G6PD expression is high in various types of cancer of cancers, including prostate, breast kidney, lung, and prostate cancers. In addition, it is associated with improved survival of cancer patients. Recent studies have revealed an increase in G6PD activity in patients with different types of cancer. Some of the cancers where G6PD is overexpressed include bladder cancer, cancer of the endometrium kidney, pancreas, and prostate cancer.

G6PD expression is closely tied to tumor size and development. Additionally G6PD is associated with poor prognosis among certain types of cancer. Although G6PD is not present in a cacancers but it is linked with poor outcomes in the melanoma. It is also linked to chronic hepatitis B virus infections, which can be a factor in the progression.

The G6PD gene is located on the distal arm of the X chromosome, alongside other genes involved in hemophilia, color-vision, and fragile X syndrome. It is approximately 18 kb long, with 13 exons and 12 introns. It contains an amino acid sequence called G6PD. The enzyme kinetics of different variants might aid in identifying these genetic conditions.

In addition to its sensitivity, in addition to its sensitivity, G6PD marker is extremely specific. This helps doctors detect malaria without the need to test malaria patients again later in their lives. It can be difficult to identify the presence of the protein in areas that are malaria-endemic. Therefore, G6PD testing should always be conducted at the time of birth. This will help save time and money, as we caas lives. However, the sensitivity and specificity of the G6PD marker will vary on the environment and the population.

Validation

Over the last 30 years, scientists have utilized G6PD to identify prostate cancer. G6PD activity is present in benign prostatic hyperplasia is 4 times greater than that in prostate cancer. G6PD is associated with poor treatment with radiotherapy and chemotherapy in prostate cancer. G6PD needs to be validated before it can be used for diagnosis of prostate cancer and to determine the response to treatment.

The validation study served the primary objective of assessing G6PD activity in a point of care test. Researchers assessed hemoglobin levels in blood samples of participants to determine its specificity and sensitivity. They also compared the results against the results of a reference test. The validation study revealed an 85% agreement between blood samples' G6PD activity and a reference assay.

The gene is responsible for the production of NADPH in the body. G6PD insufficiently affects the production of superoxide anion. This oxidant is vital in mediating the vascular system's response to Ang II. A mouse that is G6PD deficient is less responsive to Ang II, indicating that this gene is essential in regulating vascular response. G6PD deficiency decreases Akt and ERK the rate of phosphorylation in response to Ang II.

This gene controls cancer ce casurvival in anoxic environments. Its abnormal Acetylation has been associated with cancer growth and invasion. Additionally glycosylation stimulates the PPP. In addition, G6PD has been associated with hypoxia-inducible factor-1a, which is found in abundance in human tumor ce cs. Hypoxia-inducible factor-1a plays a role in promoting tumor growth and metastasis. HIF-1a's activity could be slowed by inhibition of G6PD. This is achieved by reducing NADPH levels.

References

G6PD gene and G6PD protein product are essential components of a metabolic nexus. Understanding their activity and regulation can help to understand the inner workings of ce cs as we caas the mechanisms of disease. G6PD is controlled by inter-acting signals like signaling proteins or translocation of ce cs. The G6PD marker's references in Boster bioasummarize recent studies on this enzyme. It is not known if the gene is expressed at various locations within ce cs.

The G6PD gene encodes a protein that has the amino acid sequence G6PDH. It is highly conserved, and has two amino acid residues that are required for enzyme activity , as we caas an heptapeptide peptide sequence that codes for the dinucleotide binding site. The G6PD protein is 514 amino acids long and contains 13 exons. Two amino acid binding sites are found in the protein: one for NADP, and one for G6P. G6PD also regulates transcription of Myocd-restricted genes.

The G6PD gene has been demonstrated to be a contributor to the pathogenesis of vascular disease and is implicated in metabolic reprogramming. It is also involved in the etiology of the occlusive vascular diseases two diseases that are linked to metabolic syndrome. G6PD function can be inhibited through pharmacological or genetic methods. This blocks the reprogramming of blood vessecs. The pharmacological and genetic inhibition of G6PD expression reduces vascular elastance , and decreases occlusive lesions in coronaries.

There are two main categories of people who show G6PD deficiency. There are approximately 400 million people who have an G6PD activity below 60%. This is typically considered to be a deficiency. However, in a few instances it is found that the activity levels are less than 60 percent of the normal level. A G6PD activity level of 90 percent or less is enough to seriously affect ce cafunction and life span.